XML Template (2009) [7.9.2009–9:27am] [1–14]
{TANDF_FPP}CMO/CMO_A_370737(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
MF CI).
þ
98.7)
C0
165.1)
C0
(95%
b.i.d.
b.i.d. 77.3 56.1
8.2)
0.11)
122.5
92.6
50.4 45.6
4.4 4.5
0.5)
0.13 0.15
mg
mg
132
C6 C6
117.1,
129
C6
C6
C6 C6 4.5,
129
C6 C6
0.4,
114
C6 C6
50
196.1, 118
(
C0
(
C0
(
C0
(
C0 (0.07,
change
1000
280.3 166.6
521.7
331.8
77.2 81.0
10.4 10.6
1.9 0.1
0.17 0.26
0.09
mean
107.9 LS
Sitagliptin
C0
180.6
C0 as
MF
expressed
þ
are
80.0)
129.8)
b.i.d
C0
C0
b.i.d.
78.8 60.2
0.10)
data
123.0
98.5
61.0 52.7
12.3)
4.4 4.1
1.1)
0.15 0.15
mg
99.2,
C6
1.1,
50
mg
121
C6 C6
123
C6
C6
161.5, 105
C6
120
C6 C6
C6 C6
(
C0
(
C0 (
C0
(0.2,
105
(0.06,
500 281.6 186.2
523.0
369.1
83.1 88.3
10.1 10.8
0.18 0.25
baseline
89.6
5.6
0.6
0.08
from
population).
C0 145.7
Sitagliptin
C0
change
(CAPT
phase
b.i.d.
deviation;
66.5)
112.9)
mg
C0
C0
2.0)
0.1)
77.4 55.9
0.06)
116.2
93.4
51.0 50.2
4.2 4.0
C0
0.15 0.15
C6
11.5, C6 C6
1.0,
continuation
1000 116
C6 C6
86.1,
C6
C6
99 C6 C6
standard
(
C0
112 146.1, 104
C6
(
C0
(
C0
116
(
C0 (0.02,
C6
the 276.5 197.2
519.9
382.9
85.6 80.5
11.0 10.4
4.7
0.19 0.23
in 76.3 C0
0.5
C0
0.04
mean
C0 129.5
as
and
Metformin
C0
A
phase
expressed
are
both
in
b.i.d.
47.6)
70.9)
C0
data curve.
mg
C0
63.9 61.1 96.8 94.4
0.07) 54
53.1 63.7
11.5)
4.2 4.5
0.6)
0.13 0.18
therapy
500 92
C6 C6
69.6, 94
C6 C6
107.1,
87 C6 C6 3.3, 96
C6 C6
0.4,
85 C6 C6
(
C0
(
C0 (
C0 (
C0 (0.02,
week
268.7 212.7 502.0 418.9
89.7 91.4
11.0 10.9
0.19 0.23
and
active
58.6
4.1
0.1
89.0
0.05
Metformin
C0
C0 concentration–time
baseline
the
receiving
under
analysis;
groups
q.d.
34.6) 48.7)
the
area
for
mg
C0 C0
75.8 69.9
0.09)
106.7 112.8 48.6 55.8
23.2)
4.4 4.0
1.8)
0.12 0.17
in
100
meal
87
C6 C6
57.2, 86
C6 C6
86.7, 78
C6 C6
C6
(
C0
(7.6,
86
C6
(
C0
(0.7,
77 C6 C6
AUC,
(0.04,
260.1 222.4
492.0 437.0
75.9 92.4
10.4 11.6
0.17 0.23 included
15.4
1.2
45.9 67.7
0.06
glucose;
standard
Sitagliptin
C0 C0
data
a
to
plasma
n
evaluable
n
n
n
with
responses
n
AUC,
C1
h/dL),
C1
h/mL),
postprandial
C1
h/mL),
(ng
(mg/dL),
baseline (mg baseline
(
m
IU
baseline baseline baseline
patients
PPG,
of
AUC
Postprandial PPG
from
AUC
from from from from
54 54
AUC
54 54
AUC/glucose
54
4. number metformin;
¼
Parameter 2-hour Baseline Week Change Glucose Baseline Week Change Insulin Baseline Week Change C-peptide Baseline Week Change Insulin Baseline Week Change n MF,
Table
10
54-week efficacy and safety of sitagliptin/metformin Williams-Herman et al. www.cmrojournal.com
!
2009 Informa UK Ltd
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34